HEMGENIX FUNDAMENTALS EXPLAINED

Amount of qualified patients: CDEC discussed the uncertainty in the number of patients with moderately severe to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some patients who will be categorised as acquiring delicate or reasonable illness might have a severe ble